There has been a lot of buzz around Cassava Sciences (SAVA) recently; The biotech is on a quest to achieve what so many others have failed to do - bring a viable Alzheimer’s treatment to market. According to H.C. Wainwright analyst Vernon Bernardino, the company has the potential to deliver on its promise. Driving the bull case for Cassava is simufilam, its Alzheiemr’s disease (AD) candidate for which the company recently released encouraging data from an open-label clinical trial. Following 6 months of treatment, simufilam was found to improve cognitive functions and patients’ behavior.